Physician profile
Mohammed A Ali
NPI 1962668574
$18,785.02
in general payments reported to CMS, 2019-2025
53 companies · $2,758 in 2025
The $2,758 reported for 2025 was more than what 75% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,184 · 2020: $2,350 · 2021: $2,679 · 2022: $2,409 · 2023: $3,008 · 2024: $2,397 · 2025: $2,758.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,934 · Education: $229.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,933.96 |
| Education | $228.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,130.55 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Amgen INC. | $2,994.56 | 2019-2025 | Enbrel, Otezla, Evenity |
| Pfizer INC. | $1,290.36 | 2019-2025 | |
| Ucb, INC. | $1,254.60 | 2019-2025 | Cimzia, Bimzelx |
| Mallinckrodt Hospital Products INC. | $1,019.20 | 2020-2025 | Acthar |
| Janssen Biotech, INC. | $1,011.76 | 2019-2025 | Tremfya |
| Lilly USA, LLC | $915.68 | 2019-2025 | Taltz, Olumiant, Zepbound |
| Astrazeneca Pharmaceuticals LP | $677.96 | 2021-2025 | Saphnelo, Flumist Quadrivalent |
| Glaxosmithkline, LLC. | $572.14 | 2019-2025 | Benlysta, Nucala |
| Novartis Pharmaceuticals Corporation | $555.77 | 2019-2022 | |
| Horizon Therapeutics Plc | $415.56 | 2019-2023 | Krystexxa |
| Ani Pharmaceuticals, INC. | $408.51 | 2022-2025 | Purified Cortrophin Gel |
| Radius Health, INC. | $404.70 | 2019-2025 | Tymlos |
| Harmony Biosciences LLC | $388.46 | 2020-2024 | Wakix |
| Genzyme Corporation | $327.96 | 2019-2024 |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammed Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.